[{"AccountsPayableAndAccruedLiabilitiesCurrent_0_Q3_USD":6153000.0,"ResearchAndDevelopmentExpense_1_Q3_USD":21580000.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":2903000.0,"PropertyPlantAndEquipmentGross_0_Q3_USD":6148000.0,"ProceedsFromStockOptionsExercised_3_Q3_USD":1289000.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3_Q3_USD":69113000.0,"ProceedsFromIssuanceOfCommonStock_3_Q3_USD":87534000.0,"PrepaidInsurance_0_Q3_USD":1264000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":10648000.0,"PreferredStockValue_0_Q3_USD":null,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"PreferredStockSharesIssued_0_Q3_shares":0.0,"ResearchAndDevelopmentExpense_3_Q3_USD":59651000.0,"PreferredStockSharesAuthorized_0_Q3_shares":10000000.0,"PaymentsToAcquirePropertyPlantAndEquipment_3_Q3_USD":418000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_3_Q3_USD":23380000.0,"OtherNoncashIncomeExpense_3_Q3_USD":-8000.0,"OtherLiabilitiesCurrent_0_Q3_USD":912000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3_Q3_USD":-37000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q3_USD":-22000.0,"OtherComprehensiveIncomeLossNetOfTax_3_Q3_USD":-37000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q3_USD":-22000.0,"OtherAssetsCurrent_0_Q3_USD":959000.0,"OperatingLeaseRightOfUseAsset_0_Q3_USD":1983000.0,"OperatingLeaseLiabilityNoncurrent_0_Q3_USD":3322000.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.001,"RestrictedCash_0_Q3_USD":500000.0,"RestrictedCashNoncurrent_0_Q3_USD":500000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-244461000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_3_Q3_USD":1289000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q3_USD":487000.0,"StockIssuedDuringPeriodValueNewIssues_3_Q3_USD":87534000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q3_USD":14976000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3_Q3_USD":522000.0,"StockIssuedDuringPeriodSharesStockOptionsExercised_3_Q3_shares":147.0,"StockholdersEquity_0_Q3_USD":193590000.0,"ShortTermInvestments_0_Q3_USD":31789000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3_Q3_USD":17.36,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3_Q3_USD":8.77,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0_Q3_USD":15.52,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0_Q3_shares":6606.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0_Q3_USD":41984000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0_Q3_USD":15.52,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0_Q3_shares":6606.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0_Q3_USD":41984000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3_Q3_USD":12.47,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3_Q3_shares":2591.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_3_Q3_USD":18.96,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3_Q3_USD":1600000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0_Q3_USD":12.74,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0_Q3_shares":2834.0,"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0_Q3_USD":26161000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3_Q3_pure":0.0,"ShareBasedCompensation_3_Q3_USD":12194000.0,"OperatingIncomeLoss_3_Q3_USD":-76814000.0,"OperatingIncomeLoss_1_Q3_USD":-27807000.0,"OperatingExpenses_3_Q3_USD":76814000.0,"OperatingExpenses_1_Q3_USD":27807000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-27873000.0,"CommonStocksIncludingAdditionalPaidInCapital_0_Q3_USD":438063000.0,"CommonStockSharesOutstanding_0_Q3_shares":38620000.0,"CommonStockSharesIssued_0_Q3_shares":38624000.0,"CommonStockSharesAuthorized_0_Q3_shares":200000000.0,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.001,"CommitmentsAndContingencies_0_Q3_USD":null,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3_Q3_USD":68449000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q3_USD":162036000.0,"CashCashEquivalentsAndShortTermInvestments_0_Q3_USD":193300000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":161536000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q3_USD":31789000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q3_USD":31800000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q3_USD":17000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q3_USD":6000.0,"AssetsCurrent_0_Q3_USD":203973000.0,"Assets_0_Q3_USD":209359000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_Q3_shares":6611000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":12194000.0,"AllocatedShareBasedCompensationExpense_1_Q3_USD":4555000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3_Q3_USD":12194000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q3_USD":4555000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q3_USD":-12000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q3_USD":3245000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_3_Q3_USD":-236000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-76884000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":38309000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_0_Q3_Security":0.0,"DepreciationAndAmortization_3_Q3_USD":687000.0,"NumberOfOperatingSegments_3_Q3_Segment":1.0,"NonoperatingIncomeExpense_3_Q3_USD":-33000.0,"NonoperatingIncomeExpense_1_Q3_USD":-44000.0,"NetIncomeLoss_3_Q3_USD":-76847000.0,"NetIncomeLoss_1_Q3_USD":-27851000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-65689000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":45315000.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":88823000.0,"LiabilitiesCurrent_0_Q3_USD":12440000.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":209359000.0,"Liabilities_0_Q3_USD":15769000.0,"InvestmentIncomeInterest_3_Q3_USD":77000.0,"InvestmentIncomeInterest_1_Q3_USD":24000.0,"InterestReceivableCurrent_0_Q3_USD":86000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3_Q3_USD":3996000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3_Q3_USD":2395000.0,"GeneralAndAdministrativeExpense_3_Q3_USD":17163000.0,"GeneralAndAdministrativeExpense_1_Q3_USD":6227000.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_3_Q3_USD":0.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_3_Q3_USD":0.0,"FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_3_Q3_USD":0.0,"FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_3_Q3_USD":0.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0_Q3_USD":44800000.0,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-2.13,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-0.73,"DeferredCompensationLiabilityClassifiedNoncurrent_0_Q3_USD":7000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":36147000.0,"Ticker":"CRNX","CIK":"1658247","name":"CRINETICS PHARMACEUTICALS, INC.","OfficialName":"Crinetics Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20210930","fy":"2021.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1104302360.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20211105"}]